QYUNS-B (02509) surged over 10% again, rising 9.64% to HK$27.74 as of press time, with trading volume reaching HK$18.69 million.

On the news front, QYUNS-B previously announced its first half 2025 results, reporting revenue of RMB 206 million, up 359.69% year-over-year, while losses narrowed to RMB 30.93 million, down 83.11% year-over-year. The substantial revenue growth primarily stemmed from upfront payments and milestone payments from out-licensing projects, clinical development service fees, and CDMO revenue.

Securities analysts noted that the company is a leader in domestic autoimmune innovative drugs, with solid foundations in the autoimmune drug field. The company's mature pipeline is gradually entering the monetization phase, enhancing cash generation capabilities, while its innovative pipeline welcomes overseas expansion opportunities.

Notably, QYUNS-B currently has one commercialized product - Seleixin, China's first ustekinumab biosimilar. Seleixin received approval from China's National Medical Products Administration in October 2024. As of June 2025, QYUNS-B has shipped over 60,000 units to China Medical System Eastern (a wholly-owned subsidiary of Huadong Medicine).

QYUNS-B's second-largest shareholder is Huadong Medicine, which operates a sales network spanning over 30 provinces, autonomous regions, and municipalities nationwide, with a sales force exceeding 10,000 people. Therefore, in the domestic market, QYUNS-B can leverage Huadong Medicine's sales channels to distribute products, thereby accelerating commercialization.

Under Huadong Medicine's sales efforts, QYUNS-B's commercialized product Seleixin has been prescribed by over 1,200 hospitals in the first half of the year, with market sales gradually gaining momentum.